Skip to content

Study · Non-randomized trial · n = 9 · 1992

10 results

The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration.

Bowers CY, Alster DK, Frentz JM

The Journal of clinical endocrinology and metabolism1 Feb 1992Cited by 48 (Europe PMC)

PMID1730807 (opens in a new tab)DOI10.1210/jcem.74.2.1730807 (opens in a new tab)PepBankPUB-01730807
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In short stature children, oral GHRP produced adult-like responses in four, low responses in three, and undetectable responses in two.

    In plain wordsIn short stature children, oral GHRP produced variable GH responses.

    Peptide
    GHRP-6
    Outcome
    MixedGH responses in children
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms/kg · oralAs given in this study (human).

    Measurements

    Children with GH response like normal men
    4 children
    300 micrograms/kg oral GHRP, of 9 children
    Children with low but measurable GH response
    3 children
    300 micrograms/kg oral GHRP, of 9 children
    Children with undetectable GH response
    2 children
    300 micrograms/kg oral GHRP, of 9 children

    Source sentences

    Summary
    The magnitude and pattern of the GH response to oral GHRP in four of the nine children were essentially the same as those in the five normal men. In the other five children, the GH responses were low but still measurable in three and undetectable in two of the children.
    1 context sentence
    Summary · context
    The oral GHRP dose administered to all of the children was 300 micrograms/kg, because this dosage was found to consistently increase GH levels in adults.
  2. 02HumanNon-randomized trialEfficacy outcome

    In normal men, oral GHRP raised GH at 30 min, peaked at 60-75 min, and returned to baseline at 150-180 min.

    In plain wordsIn normal men, oral GHRP increased GH, then GH returned to baseline.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response timing
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms/kg · oralAs given in this study (human).

    Measurements

    Time to detectable GH rise
    30 min
    300 micrograms/kg oral GHRP
    Time to peak GH
    60 to 75 min
    300 micrograms/kg oral GHRP
    Time to return to baseline GH
    150 to 180 min
    300 micrograms/kg oral GHRP

    Source sentences

    Summary
    At the 300 micrograms/kg dosage, the GH rise was detectable at 30 min, peaked between 60-75 min, and gradually declined to the baseline level between 150-180 min.
    1 context sentence
    Summary · context
    Because of the clinical value of having an orally active peptide to release GH, five normal men were given GHRP orally at dosages of 100 and 300 micrograms/kg.
  3. 03HumanNon-randomized trialEfficacy outcome

    In normal men, GHRP increased peak GH 63-fold above baseline at the lower oral dose.

    In plain wordsIn normal men, the lower oral GHRP dose increased peak GH above baseline.

    Peptide
    GHRP-6
    Outcome
    IncreasePeak GH at lower dose
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 micrograms/kg · oralAs given in this study (human).

    Measurements

    Peak GH rise
    63 fold
    100 micrograms/kg

    Source sentences

    Summary
    Peak GH levels rose 63- and 202-fold above the baseline after administration of 100 and 300 micrograms/kg GHRP, respectively.
    1 context sentence
    Summary · context
    Because of the clinical value of having an orally active peptide to release GH, five normal men were given GHRP orally at dosages of 100 and 300 micrograms/kg.
  4. 04HumanNon-randomized trialEfficacy outcome

    In normal men, GHRP increased peak GH 202-fold above baseline at the higher oral dose.

    In plain wordsIn normal men, the higher oral GHRP dose increased peak GH above baseline.

    Peptide
    GHRP-6
    Outcome
    IncreasePeak GH at higher dose
    Study

    n = 5

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms/kg · oralAs given in this study (human).

    Measurements

    Peak GH rise
    202 fold
    300 micrograms/kg

    Source sentences

    Summary
    Peak GH levels rose 63- and 202-fold above the baseline after administration of 100 and 300 micrograms/kg GHRP, respectively.
    1 context sentence
    Summary · context
    Because of the clinical value of having an orally active peptide to release GH, five normal men were given GHRP orally at dosages of 100 and 300 micrograms/kg.
  5. 05HumanNon-randomized trialPharmacokinetics

    In normal men, oral GHRP appeared in serum within 15 min, peaked at 60 min, and declined more slowly than GH.

    In plain wordsIn normal men, oral GHRP appeared in blood before its peak and declined more slowly than GH.

    Peptide
    GHRP-6
    Outcome
    Not applicableOral concentration profile
    Study

    n = 5

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    300 micrograms/kg · oralAs given in this study (human).

    Measurements

    Time to measurable serum irGHRP
    ≤ 15 min
    300 micrograms/kg oral GHRP
    Time to peak serum irGHRP
    60 min
    300 micrograms/kg oral GHRP

    Source sentences

    Summary
    After administration of 300 micrograms/kg GHRP orally to normal men, serum irGHRP was measurable within 15 min, the peak serum irGHRP level coincided with the GH rise at 60 min, and serum irGHRP levels fell more slowly than serum GH levels.
  6. 06HumanNon-randomized trialActivity measurement

    In normal men, oral GHRP had about 0.3% of intravenous GHRP activity.

    In plain wordsIn normal men, oral GHRP had less GH-releasing activity than intravenous GHRP.

    Peptide
    GHRP-6
    Outcome
    DecreaseOral relative activity
    Study

    n: not reported in source

    Comparator
    Intravenous GHRP
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    300 micrograms/kg · oralAs given in this study (human).

    Measurements

    Relative activity
    ≈ 0.3%
    oral versus intravenous

    Source sentences

    Summary
    Since 300 micrograms/kg oral GHRP released about the same amount of GH as 1 microgram/kg, iv, in normal men, it was calculated that oral GHRP has about 0.3% the activity of iv GHRP.
  7. 07HumanNon-randomized trialPharmacokinetics

    In normal men, intravenous GHRP produced immediate dose-proportional peak serum levels, followed by an exponential decline.

    In plain wordsIn normal men, intravenous GHRP reached peak blood levels immediately, then declined.

    Peptide
    GHRP-6
    Outcome
    Not applicableIntravenous concentration profile
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0.1, 0.3, and 1.0 micrograms/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    After iv GHRP, the peak serum irGHRP levels were immediate and proportional to the dosage, and the disappearance rate decreased exponentially.
    1 context sentence
    Summary · context
    For comparison of serum irGHRP and GH levels, results were included after iv bolus administration of 0.1, 0.3, and 1.0 micrograms/kg GHRP to normal men.
  8. 08HumanNon-randomized trialPharmacokinetics

    After intravenous GHRP in normal men, the mean serum irGHRP level between 100-240 min was essentially the same and remained slightly elevated.

    In plain wordsAfter intravenous GHRP, blood levels remained slightly elevated during the late sampling period.

    Peptide
    GHRP-6
    Outcome
    Not applicableLate serum concentrations
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Between 100-240 min, the mean serum irGHRP level was essentially the same and remained slightly elevated.
    1 context sentence
    Summary · context
    After iv GHRP, the peak serum irGHRP levels were immediate and proportional to the dosage, and the disappearance rate decreased exponentially.
  9. 09HumanNon-randomized trialPharmacokinetics

    GHRP had a serum half-life of 20 min after oral and intravenous administration.

    In plain wordsGHRP had the same reported blood half-life after oral and intravenous administration.

    Peptide
    GHRP-6
    Outcome
    Not applicableSerum half-life
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oral and intravenousAs given in this study (human).

    Measurements

    Half-life
    20 min
    oral and intravenous

    Source sentences

    Summary
    The serum half-life was 20 min, and the distribution volume was 2.5 L after both oral and iv administration.
  10. 10HumanNon-randomized trialPharmacokinetics

    GHRP had a distribution volume of 2.5 L after oral and intravenous administration.

    In plain wordsGHRP had the same reported distribution volume after oral and intravenous administration.

    Peptide
    GHRP-6
    Outcome
    Not applicableDistribution volume
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oral and intravenousAs given in this study (human).

    Measurements

    Distribution volume
    2.5 L
    oral and intravenous

    Source sentences

    Summary
    The serum half-life was 20 min, and the distribution volume was 2.5 L after both oral and iv administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:59 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.